Osteoprotegerin Active Protein | OPG active protein

Recombinant Human Osteoprotegerin

Cat. Num. AAA145090

• Gene Names: TNFRSF11B; OPG; TR1; OCIF
• Purity: Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
• Synonyms: Osteoprotegerin; Recombinant Human Osteoprotegerin; OPG Human; Osteoprotegerin Human Recombinant; TNFRSF11B; OPG; OCIF; Osteoclastogenesis inhibitory factor; TR1; MGC29565; OPG active protein

• Host: E Coli
• Purity/Purification: Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
• Form/Format: The OPG was lyophilized from a 0.2 um filtered concentrated (0.5mg/ml) solution in PBS, pH 7.4.; Sterile Filtered White lyophilized (freeze-dried) powder.
• Sequence: METFPPKYLH YDEETSHQLL CDKCPPGTYL KQHCTAKWKT VCAPCPDHYY TDSWHTSDEC LYCSPVCKEL QYVKQECNRT HNRVCECKEG RYLEIEFCLK HRSCPPGFGV VQAGTPERNT VCKRCPDGFF SNETSSKAPC RKHTNCSVFG LLLTQKGNAT HDNICSGNSE STQK
• Sequence Length: 401

• Solubility: It is recommended to reconstitute the lyophilized Osteoprotegerin in sterile 18M Omega -cm H2O not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.
• Biological Activity: The activity is determined by its ability to neutralize the stimulation of U937 cells treated with 10ng/ml of soluble RANKL corresponding to a specific activity of 100,000IU/mg.
• Preparation and Storage: Lyophilized Osteoprotegerin although stable at room temperature for 3 weeks, should be stored desiccated below -18 degree C. Upon reconstitution OCIF should be stored at 4 degree C between 2-7 days and for future use below -18 degree C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.

Related Product Information for OPG active protein

Description: Recombinant Human Osteoprotegerin produced in E Coli cells is a single, non-glycosylated, polypeptide chain containing 174 amino acids and having a molecular mass of 20kDa. The OPG is purified by proprietary chromatographic techniques.

Introduction: Osteoprotegerin acts as decoy receptor for rankl and thereby neutralizes its function in osteoclastogenesis. OPG inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local rankl/opg ratio. Osteoprotegerin may also play a role in preventing arterial calcification. May act as decoy receptor for trail and protect against apoptosis. Trail binding blocks the inhibition of osteoclastogenesis.

Product Categories/Family for OPG active protein

Cytokines and Growth Factors; Growth Factors; Osteoprotegerin

NCBI and Uniprot Product Information

• NCBI GI #: 148743793
• NCBI GeneID: 4982
• NCBI Accession #: NP_002537.3
• NCBI GenBank Nucleotide #: NM_002546.3
• UniProt Accession #: O00300; O60236; Q53FX6; Q9UHP4; B2R9A8
• Molecular Weight: 46,026 Da
• NCBI Official Full Name: tumor necrosis factor receptor superfamily member 11B
• NCBI Official Synonym Full Names: tumor necrosis factor receptor superfamily, member 11b
• NCBI Official Symbol: TNFRSF11B
• NCBI Official Synonym Symbols: OPG; TR1; OCIF
• NCBI Protein Information: tumor necrosis factor receptor superfamily member 11B; osteoclastogenesis inhibitory factor; osteoprotegerin
• UniProt Protein Name: Tumor necrosis factor receptor superfamily member 11B
• UniProt Gene Name: TNFRSF11B
• UniProt Synonym Gene Names: OCIF; OPG
• UniProt Entry Name: TR11B_HUMAN

NCBI Description

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

Uniprot Description

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal.

Protein type: Inhibitor; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 8q24

Cellular Component: extracellular space; proteinaceous extracellular matrix; extracellular region

Molecular Function: cytokine activity; receptor activity

Biological Process: response to drug; response to magnesium ion; extracellular matrix organization and biogenesis; apoptosis; negative regulation of odontogenesis of dentine-containing teeth; response to estrogen stimulus; response to arsenic; negative regulation of bone resorption; signal transduction; skeletal development; response to nutrient

Disease: Paget Disease, Juvenile